Aridis Pharmaceuticals (ARDS) Competitors $0.0017 +0.00 (+30.77%) As of 09/26/2025 09:30 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock ARDS vs. BON, PBLA, VINC, AMPE, NCNA, VRPX, SMFL, NEXI, SCPS, and VAXXShould you be buying Aridis Pharmaceuticals stock or one of its competitors? The main competitors of Aridis Pharmaceuticals include Bon Natural Life (BON), Panbela Therapeutics (PBLA), Vincerx Pharma (VINC), Ampio Pharmaceuticals (AMPE), NuCana (NCNA), Virpax Pharmaceuticals (VRPX), Smart for Life (SMFL), NexImmune (NEXI), Scopus BioPharma (SCPS), and Vaxxinity (VAXX). These companies are all part of the "pharmaceutical products" industry. Aridis Pharmaceuticals vs. Its Competitors Bon Natural Life Panbela Therapeutics Vincerx Pharma Ampio Pharmaceuticals NuCana Virpax Pharmaceuticals Smart for Life NexImmune Scopus BioPharma Vaxxinity Aridis Pharmaceuticals (NASDAQ:ARDS) and Bon Natural Life (NASDAQ:BON) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations. Do insiders & institutionals hold more shares of ARDS or BON? 9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.6% of Bon Natural Life shares are owned by institutional investors. 5.5% of Aridis Pharmaceuticals shares are owned by company insiders. Comparatively, 26.5% of Bon Natural Life shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is ARDS or BON more profitable? Company Net Margins Return on Equity Return on Assets Aridis PharmaceuticalsN/A N/A N/A Bon Natural Life N/A N/A N/A Does the media prefer ARDS or BON? In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Bon Natural Life'saverage media sentiment score. Company Overall Sentiment Aridis Pharmaceuticals Neutral Bon Natural Life Neutral Which has higher earnings and valuation, ARDS or BON? Bon Natural Life has higher revenue and earnings than Aridis Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAridis PharmaceuticalsN/AN/A-$30.37MN/AN/ABon Natural Life$23.84M0.01$400KN/AN/A Which has more risk and volatility, ARDS or BON? Aridis Pharmaceuticals has a beta of 43.79, suggesting that its share price is 4,279% more volatile than the S&P 500. Comparatively, Bon Natural Life has a beta of -0.46, suggesting that its share price is 146% less volatile than the S&P 500. SummaryBon Natural Life beats Aridis Pharmaceuticals on 3 of the 5 factors compared between the two stocks. Get Aridis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARDS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARDS vs. The Competition Export to ExcelMetricAridis PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$91K$872.56M$5.70B$10.39BDividend YieldN/A4.84%5.78%4.69%P/E RatioN/A1.2576.9626.24Price / SalesN/A26.22558.03126.78Price / CashN/A17.6425.6330.64Price / BookN/A6.5812.406.38Net Income-$30.37M-$5.42M$3.31B$274.27M7 Day PerformanceN/A-0.96%0.24%-0.75%1 Month PerformanceN/A2.80%3.88%6.30%1 Year PerformanceN/A27.94%62.64%27.41% Aridis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARDSAridis PharmaceuticalsN/A$0.00+30.8%N/AN/A$91KN/A0.0030Gap DownBONBon Natural LifeN/A$1.87-7.9%N/AN/A$340K$23.84M0.00100PBLAPanbela Therapeutics0.0847 of 5 stars$0.05-0.2%N/A-85.7%$243KN/A0.006VINCVincerx Pharma2.8183 of 5 stars$0.04-18.3%$40.00+104,338.6%-99.6%$200KN/A0.0060AMPEAmpio PharmaceuticalsN/A$0.11+3,870.4%N/A+22.7%$122KN/A-0.0120NCNANuCana1.6232 of 5 stars$3.89-3.0%N/A-99.2%$120KN/A-0.0130VRPXVirpax Pharmaceuticals0.1458 of 5 stars$0.03+13.1%N/A-99.9%$31KN/A0.007SMFLSmart for LifeN/A$0.00+100.0%N/A-93.2%$21K$11.11M0.00110Gap UpNEXINexImmuneN/A$0.01flatN/A-99.9%$14KN/A0.0070SCPSScopus BioPharmaN/A$0.00flatN/A+0.0%$13KN/A0.009High Trading VolumeVAXXVaxxinityN/A$0.00flatN/A-50.0%$13KN/A0.0090Gap Down Related Companies and Tools Related Companies BON Alternatives PBLA Alternatives VINC Alternatives AMPE Alternatives NCNA Alternatives VRPX Alternatives SMFL Alternatives NEXI Alternatives SCPS Alternatives VAXX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARDS) was last updated on 9/29/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aridis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aridis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARDS Stock Alerts